Study tracks Real-World use of advanced breast cancer drug
NCT ID NCT06386263
Summary
This study observed how patients with advanced HER2-positive or HER2-low breast cancer used the drug trastuzumab deruxtecan (T-DXd) in routine Canadian clinics. Researchers tracked 22 patients to see how often treatment was stopped early or doses were changed, and how long patients stayed on the medication. The goal was to understand how the drug performs outside of controlled clinical trials in everyday medical practice.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Oakville, Ontario, L6H1A7, Canada
Conditions
Explore the condition pages connected to this study.